Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation
Purpose Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of clinical features and novel biomarkers of cell cycle-progression in age-dependent subgroups of TNBC patients. Methods One hun...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2022-12, Vol.196 (3), p.471-482 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 482 |
|---|---|
| container_issue | 3 |
| container_start_page | 471 |
| container_title | Breast cancer research and treatment |
| container_volume | 196 |
| creator | Vihervuori, H. Korpinen, K. Autere, T. A. Repo, H. Talvinen, K. Kronqvist, P. |
| description | Purpose
Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of clinical features and novel biomarkers of cell cycle-progression in age-dependent subgroups of TNBC patients.
Methods
One hundred forty seven TNBC patients with complete clinical data and up to 18 year follow-up were collected from Turku University Hospital, Finland. Eight biomarkers for cell division were immunohistochemically detected to evaluate their clinical applicability in relation to patient and tumor characteristics.
Results
Age at diagnosis was the decisive factor predicting disease-specific mortality in TNBC (
p
= 0.002). The established prognostic features, nodal status and Ki-67, predicted survival only when combined with age. The outcome and prognostic features differed significantly between age groups, middle-aged patients showing the most favorable outcome. Among young patients, only lack of basal differentiation predicted disease outcome, indicating 4.5-fold mortality risk (
p
= 0.03). Among patients aged > 57, the established prognostic features predicted disease outcome with up to 3.0-fold mortality risk for tumor size ≥ 2 cm (
p
= 0.001). Concerning cell proliferation, Ki-67 alone was a significant prognosticator among patients aged > 57 years (
p
= 0.009). Among the studied cell cycle-specific biomarkers, only geminin predicted disease outcome, indicating up to 6.2-fold increased risk of mortality for tumor size |
| doi_str_mv | 10.1007/s10549-022-06767-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9633490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A725053496</galeid><sourcerecordid>A725053496</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-7b85e3c7985f081cd8bd2518d363d7daa50eebe15cd97ced0a741273c77348e93</originalsourceid><addsrcrecordid>eNp9ks2KFDEUhQtRnHH0BVxIQBA3Neank1RthGHwDwbcqNuQTm5VZ0gnbVLVMDvBR_ANfRJv2-PMtIhkEcj9zrm5l9M0Txk9ZZTqV5VRuehbynlLlVa6ZfeaYya1aDVn-n5zTBk-qo6qo-ZRrZeU0l7T_mFzJBRXTEt23Hz_YstVSCPJ8-TyGirJA5lK2ERoE4x2ClsgywK2TsTZ5KCQkIgPwwAF0kTsCGQsed7Un99-bEoeU65TcGRr4ww7LxdDCs5GMoCd5oINbPIEyRjQAv1zetw8GGys8OT6Pmk-v33z6fx9e_Hx3Yfzs4vWScqnVi87CcLpvpMD7Zjz3dJzyTovlPDaWyspwBKYdL7XDjy1esG4RoUWiw56cdK83vtu5uUavMP_FxvNpoQ1LsFkG8xhJYWVGfPW9EqIRU_R4OW1QclfZ6iTWYfqIEabIM_VcM1VzzmnC0Sf_4Ve5rkkHA8pwRTruaS31GgjmJCGjH3dztScaQQktlVInf6DwuNhHVxOMAR8PxC8uCNYgY3TquY475ZdD0G-B13JtRYYbpbBqNllzOwzZjBj5nfGDEPRs7trvJH8CRUCYg9ULKURyu3s_7H9BcLL3uU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2731619250</pqid></control><display><type>article</type><title>Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Vihervuori, H. ; Korpinen, K. ; Autere, T. A. ; Repo, H. ; Talvinen, K. ; Kronqvist, P.</creator><creatorcontrib>Vihervuori, H. ; Korpinen, K. ; Autere, T. A. ; Repo, H. ; Talvinen, K. ; Kronqvist, P.</creatorcontrib><description>Purpose
Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of clinical features and novel biomarkers of cell cycle-progression in age-dependent subgroups of TNBC patients.
Methods
One hundred forty seven TNBC patients with complete clinical data and up to 18 year follow-up were collected from Turku University Hospital, Finland. Eight biomarkers for cell division were immunohistochemically detected to evaluate their clinical applicability in relation to patient and tumor characteristics.
Results
Age at diagnosis was the decisive factor predicting disease-specific mortality in TNBC (
p
= 0.002). The established prognostic features, nodal status and Ki-67, predicted survival only when combined with age. The outcome and prognostic features differed significantly between age groups, middle-aged patients showing the most favorable outcome. Among young patients, only lack of basal differentiation predicted disease outcome, indicating 4.5-fold mortality risk (
p
= 0.03). Among patients aged > 57, the established prognostic features predicted disease outcome with up to 3.0-fold mortality risk for tumor size ≥ 2 cm (
p
= 0.001). Concerning cell proliferation, Ki-67 alone was a significant prognosticator among patients aged > 57 years (
p
= 0.009). Among the studied cell cycle-specific biomarkers, only geminin predicted disease outcome, indicating up to 6.2-fold increased risk of mortality for tumor size < 2 cm (
p
= 0.03).
Conclusion
Traditional clinical features do not provide optimal prognostic characterization for all TNBC patients. Young age should be considered as an additional adverse prognostic feature in therapeutic considerations. Increased proliferation, as evaluated using Ki-67 or geminin immunohistochemistry, showed potential in detecting survival differences in subgroups of TNBC.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-022-06767-1</identifier><identifier>PMID: 36261751</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Age ; Age groups ; Biomarkers ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms ; Cell cycle ; Cell division ; Cell Proliferation ; Female ; Geminin ; Health aspects ; Humans ; Immunohistochemistry ; Ki-67 Antigen ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Middle Aged ; Mortality ; Oncology ; Patients ; Preclinical Study ; Prognosis ; Triple Negative Breast Neoplasms ; Tumors</subject><ispartof>Breast cancer research and treatment, 2022-12, Vol.196 (3), p.471-482</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>COPYRIGHT 2022 Springer</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-7b85e3c7985f081cd8bd2518d363d7daa50eebe15cd97ced0a741273c77348e93</citedby><cites>FETCH-LOGICAL-c502t-7b85e3c7985f081cd8bd2518d363d7daa50eebe15cd97ced0a741273c77348e93</cites><orcidid>0000-0001-8922-0648</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-022-06767-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-022-06767-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36261751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vihervuori, H.</creatorcontrib><creatorcontrib>Korpinen, K.</creatorcontrib><creatorcontrib>Autere, T. A.</creatorcontrib><creatorcontrib>Repo, H.</creatorcontrib><creatorcontrib>Talvinen, K.</creatorcontrib><creatorcontrib>Kronqvist, P.</creatorcontrib><title>Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of clinical features and novel biomarkers of cell cycle-progression in age-dependent subgroups of TNBC patients.
Methods
One hundred forty seven TNBC patients with complete clinical data and up to 18 year follow-up were collected from Turku University Hospital, Finland. Eight biomarkers for cell division were immunohistochemically detected to evaluate their clinical applicability in relation to patient and tumor characteristics.
Results
Age at diagnosis was the decisive factor predicting disease-specific mortality in TNBC (
p
= 0.002). The established prognostic features, nodal status and Ki-67, predicted survival only when combined with age. The outcome and prognostic features differed significantly between age groups, middle-aged patients showing the most favorable outcome. Among young patients, only lack of basal differentiation predicted disease outcome, indicating 4.5-fold mortality risk (
p
= 0.03). Among patients aged > 57, the established prognostic features predicted disease outcome with up to 3.0-fold mortality risk for tumor size ≥ 2 cm (
p
= 0.001). Concerning cell proliferation, Ki-67 alone was a significant prognosticator among patients aged > 57 years (
p
= 0.009). Among the studied cell cycle-specific biomarkers, only geminin predicted disease outcome, indicating up to 6.2-fold increased risk of mortality for tumor size < 2 cm (
p
= 0.03).
Conclusion
Traditional clinical features do not provide optimal prognostic characterization for all TNBC patients. Young age should be considered as an additional adverse prognostic feature in therapeutic considerations. Increased proliferation, as evaluated using Ki-67 or geminin immunohistochemistry, showed potential in detecting survival differences in subgroups of TNBC.</description><subject>Age</subject><subject>Age groups</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms</subject><subject>Cell cycle</subject><subject>Cell division</subject><subject>Cell Proliferation</subject><subject>Female</subject><subject>Geminin</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Ki-67 Antigen</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Oncology</subject><subject>Patients</subject><subject>Preclinical Study</subject><subject>Prognosis</subject><subject>Triple Negative Breast Neoplasms</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks2KFDEUhQtRnHH0BVxIQBA3Neank1RthGHwDwbcqNuQTm5VZ0gnbVLVMDvBR_ANfRJv2-PMtIhkEcj9zrm5l9M0Txk9ZZTqV5VRuehbynlLlVa6ZfeaYya1aDVn-n5zTBk-qo6qo-ZRrZeU0l7T_mFzJBRXTEt23Hz_YstVSCPJ8-TyGirJA5lK2ERoE4x2ClsgywK2TsTZ5KCQkIgPwwAF0kTsCGQsed7Un99-bEoeU65TcGRr4ww7LxdDCs5GMoCd5oINbPIEyRjQAv1zetw8GGys8OT6Pmk-v33z6fx9e_Hx3Yfzs4vWScqnVi87CcLpvpMD7Zjz3dJzyTovlPDaWyspwBKYdL7XDjy1esG4RoUWiw56cdK83vtu5uUavMP_FxvNpoQ1LsFkG8xhJYWVGfPW9EqIRU_R4OW1QclfZ6iTWYfqIEabIM_VcM1VzzmnC0Sf_4Ve5rkkHA8pwRTruaS31GgjmJCGjH3dztScaQQktlVInf6DwuNhHVxOMAR8PxC8uCNYgY3TquY475ZdD0G-B13JtRYYbpbBqNllzOwzZjBj5nfGDEPRs7trvJH8CRUCYg9ULKURyu3s_7H9BcLL3uU</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Vihervuori, H.</creator><creator>Korpinen, K.</creator><creator>Autere, T. A.</creator><creator>Repo, H.</creator><creator>Talvinen, K.</creator><creator>Kronqvist, P.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8922-0648</orcidid></search><sort><creationdate>20221201</creationdate><title>Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation</title><author>Vihervuori, H. ; Korpinen, K. ; Autere, T. A. ; Repo, H. ; Talvinen, K. ; Kronqvist, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-7b85e3c7985f081cd8bd2518d363d7daa50eebe15cd97ced0a741273c77348e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Age groups</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms</topic><topic>Cell cycle</topic><topic>Cell division</topic><topic>Cell Proliferation</topic><topic>Female</topic><topic>Geminin</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Ki-67 Antigen</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Oncology</topic><topic>Patients</topic><topic>Preclinical Study</topic><topic>Prognosis</topic><topic>Triple Negative Breast Neoplasms</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vihervuori, H.</creatorcontrib><creatorcontrib>Korpinen, K.</creatorcontrib><creatorcontrib>Autere, T. A.</creatorcontrib><creatorcontrib>Repo, H.</creatorcontrib><creatorcontrib>Talvinen, K.</creatorcontrib><creatorcontrib>Kronqvist, P.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vihervuori, H.</au><au>Korpinen, K.</au><au>Autere, T. A.</au><au>Repo, H.</au><au>Talvinen, K.</au><au>Kronqvist, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>196</volume><issue>3</issue><spage>471</spage><epage>482</epage><pages>471-482</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
Triple-negative breast cancer (TNBC) is an aggressive disease lacking specific biomarkers to guide treatment decisions. We evaluated the combined prognostic impact of clinical features and novel biomarkers of cell cycle-progression in age-dependent subgroups of TNBC patients.
Methods
One hundred forty seven TNBC patients with complete clinical data and up to 18 year follow-up were collected from Turku University Hospital, Finland. Eight biomarkers for cell division were immunohistochemically detected to evaluate their clinical applicability in relation to patient and tumor characteristics.
Results
Age at diagnosis was the decisive factor predicting disease-specific mortality in TNBC (
p
= 0.002). The established prognostic features, nodal status and Ki-67, predicted survival only when combined with age. The outcome and prognostic features differed significantly between age groups, middle-aged patients showing the most favorable outcome. Among young patients, only lack of basal differentiation predicted disease outcome, indicating 4.5-fold mortality risk (
p
= 0.03). Among patients aged > 57, the established prognostic features predicted disease outcome with up to 3.0-fold mortality risk for tumor size ≥ 2 cm (
p
= 0.001). Concerning cell proliferation, Ki-67 alone was a significant prognosticator among patients aged > 57 years (
p
= 0.009). Among the studied cell cycle-specific biomarkers, only geminin predicted disease outcome, indicating up to 6.2-fold increased risk of mortality for tumor size < 2 cm (
p
= 0.03).
Conclusion
Traditional clinical features do not provide optimal prognostic characterization for all TNBC patients. Young age should be considered as an additional adverse prognostic feature in therapeutic considerations. Increased proliferation, as evaluated using Ki-67 or geminin immunohistochemistry, showed potential in detecting survival differences in subgroups of TNBC.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36261751</pmid><doi>10.1007/s10549-022-06767-1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8922-0648</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2022-12, Vol.196 (3), p.471-482 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9633490 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Age Age groups Biomarkers Biomarkers, Tumor Breast cancer Breast Neoplasms Cell cycle Cell division Cell Proliferation Female Geminin Health aspects Humans Immunohistochemistry Ki-67 Antigen Medical research Medicine Medicine & Public Health Medicine, Experimental Middle Aged Mortality Oncology Patients Preclinical Study Prognosis Triple Negative Breast Neoplasms Tumors |
| title | Varying outcomes of triple-negative breast cancer in different age groups–prognostic value of clinical features and proliferation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T01%3A29%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Varying%20outcomes%20of%20triple-negative%20breast%20cancer%20in%20different%20age%20groups%E2%80%93prognostic%20value%20of%20clinical%20features%20and%20proliferation&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Vihervuori,%20H.&rft.date=2022-12-01&rft.volume=196&rft.issue=3&rft.spage=471&rft.epage=482&rft.pages=471-482&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-022-06767-1&rft_dat=%3Cgale_pubme%3EA725053496%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2731619250&rft_id=info:pmid/36261751&rft_galeid=A725053496&rfr_iscdi=true |